Choosing the right CRO partner is one of the most important decisions in early clinical development. This is especially true in metabolic diseases, where study design, patient recruitment, scientific methodology and operational quality can directly influence the speed and confidence of development decisions.
Through the merger with Tranquil Clinical Research, Profil is expanding its clinical operations to the United States and establishing its first US clinical research unit in the Houston metropolitan area. For pharma and biotech companies developing therapies in diabetes, obesity and related metabolic diseases, this marks an important step: Profil’s specialized metabolic expertise is now available through clinical research units in both Europe and the United States.
Left to right: Tim Heise (CSO and co-founder), Leona Plum-Mörschel (CEO of Profil Institute Holding) and Karim Mohammed (CEO of Profil USA) signing the contract.
More options for global metabolic clinical trial execution
For more than 25 years, Profil has specialized in early-phase clinical trials in metabolic diseases. Sponsors have relied on Profil for scientifically rigorous study designs, sophisticated methodologies and high-quality clinical trial execution in diabetes and obesity research.
With the new US clinical research unit, sponsors now gain additional flexibility when planning international development programs. Studies can be supported through Profil’s established clinical research unit in Neuss, Germany, as well as through the new site in Texas or as multicenter studies managed by one CRO with harmonized processes and consistently high operational standards across all sites.
This expanded footprint is particularly relevant for companies looking for a CRO partner that combines deep metabolic expertise with operational capabilities across key clinical development regions.
Access to a large and diverse US patient population
Patient recruitment is one of the most critical factors in clinical trial planning. With established clinical research units in both Neuss, Germany, and the Houston metropolitan area, Profil can now provide access to an even broader and more diverse patient pool for metabolic clinical studies.
Profil’s long-standing volunteer database and recruitment expertise in Germany remain a key strength, while the expansion into the United States adds further opportunities to support efficient enrollment across different populations and regions. Together, both locations enhance Profil’s ability to recruit suitable study participants and generate data that reflects the diversity of real-world patient populations.
This is especially important in indications such as type 2 diabetes and obesity, where patient characteristics can play a key role in clinical development.
Supporting FDA-focused development pathways
For biotech and pharma companies developing assets for the US market, having access to a US-based clinical research unit can be a strategic advantage.
Profil’s expansion to the United States creates new opportunities to support clinical development programs in closer alignment with the US clinical research environment. This can be especially valuable for sponsors planning FDA-related development pathways, early-phase studies in US populations or global programs that require both European and US clinical trial capabilities.
Specialized CRO expertise in diabetes, obesity and metabolic diseases
Metabolic clinical trials require more than operational execution. They require scientific understanding of the indication, the investigational product, the patient population and the right endpoints.
Profil’s core expertise lies in metabolic research. Over more than 25 years, Profil has supported clinical development programs in diabetes, obesity and related metabolic diseases. This specialization allows sponsors to work with a CRO partner that understands the scientific and operational challenges of metabolic drug development from the earliest phases onward.
For sponsors, this means access to:
- experienced clinical research teams focused on metabolic diseases
- scientifically robust study designs
- established processes for early-phase clinical trial execution
- advanced metabolic methodologies
- high-quality data to support confident development decisions
Faster, more flexible clinical development support
Speed matters in drug development, but speed must not come at the expense of quality. By combining Profil’s European center of excellence with the new US clinical research unit, sponsors gain more options for planning and executing studies efficiently.
The expanded clinical network can support broader recruitment opportunities and greater flexibility in selecting the right location for a given study design. For companies developing metabolic therapies, this can help reduce operational bottlenecks and support more efficient progression from early clinical development to the next decision point.
A strong transatlantic CRO partner for metabolic trials
The merger with Tranquil Clinical Research is more than a geographic expansion. It strengthens Profil’s ability to support pharma and biotech sponsors with specialized metabolic clinical research services across Europe and the United States.
For sponsors searching for a CRO partner for diabetes or obesity studies, Profil now offers a broader operational footprint while maintaining the scientific focus that has defined the company for decades.
With clinical research units in Germany and the United States, Profil is entering a new chapter of international growth and is better positioned than ever to support sponsors in bringing innovative metabolic therapies closer to patients.
Looking for a CRO partner for metabolic clinical trials?
Profil supports pharma and biotech companies in the clinical development of therapies for diabetes and obesity. With specialized expertise, advanced methodologies and clinical research units in Europe and the United States, Profil provides high-quality support for early-phase metabolic clinical trials.
Contact our team to discuss how Profil can support your next clinical development program.